{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:11:05Z","timestamp":1788865865097,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"International Science & Technology Cooperation Program of China","award":["2015DFA30920"],"award-info":[{"award-number":["2015DFA30920"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81771856"],"award-info":[{"award-number":["81771856"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science & Technology (International Science & Technology Cooperation) Research Base Construction Program of Chongqing","award":["cstc2014gjhz110004"],"award-info":[{"award-number":["cstc2014gjhz110004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s11095-020-02873-1","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T21:02:39Z","timestamp":1594760559000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Construction of Nucleolin-Targeted Lipid Nanobubbles and Contrast-Enhanced Ultrasound Molecular Imaging in Triple-Negative Breast Cancer"],"prefix":"10.1007","volume":"37","author":[{"given":"Kejing","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luofu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minmin","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daijia","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1685-4441","authenticated-orcid":false,"given":"Yanli","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,14]]},"reference":[{"issue":"20","key":"2873_CR1","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938\u201348.","journal-title":"N Engl J Med"},{"issue":"15","key":"2873_CR2","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429\u201334.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2873_CR3","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674\u201390.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"2873_CR4","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1083\/jcb.200304132","volume":"163","author":"S Christian","year":"2003","unstructured":"Christian S, Pilch J, Akerman ME, Porkka K, Laakkonen P, Ruoslahti E. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol. 2003;163(4):871\u20138.","journal-title":"J Cell Biol"},{"key":"2873_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lfs.2017.07.025","volume":"186","author":"W Jia","year":"2017","unstructured":"Jia W, Yao Z, Zhao J, Guan Q, Gao L. New perspectives of physiological and pathological functions of nucleolin (NCL). Life Sci. 2017;186:1\u201310.","journal-title":"Life Sci"},{"key":"2873_CR6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/bs.apcsb.2017.08.001","volume":"111","author":"I Ugrinova","year":"2018","unstructured":"Ugrinova I, Petrova M, Chalabi-Dchar M, Bouvet P. Multifaceted Nucleolin protein and its molecular Partners in Oncogenesis. Adv Protein Chem Struct Biol. 2018;111:133\u201364.","journal-title":"Adv Protein Chem Struct Biol"},{"issue":"7","key":"2873_CR7","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1158\/0008-5472.CAN-07-5723","volume":"68","author":"S Soundararajan","year":"2008","unstructured":"Soundararajan S, Chen W, Spicer EK, Courtenay-Luck N, Fernandes DJ. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res. 2008;68(7):2358\u201365.","journal-title":"Cancer Res"},{"issue":"3","key":"2873_CR8","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.yexmp.2009.01.004","volume":"86","author":"PJ Bates","year":"2009","unstructured":"Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO. Discovery and development of the G-rich oligonucleotide AS1411 AS a novel treatment for cancer. Exp Mol Pathol. 2009;86(3):151\u201364.","journal-title":"Exp Mol Pathol"},{"key":"2873_CR9","doi-asserted-by":"crossref","unstructured":"Bates PJ, Reyes-Reyes EM, Malik MT, Murphy EM, O'Toole MG, Trent JO. G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: Uses and mechanisms. Biochim Biophys Acta Gen Subj. 2017, 1861(5 Pt B): 1414\u20131428.","DOI":"10.1016\/j.bbagen.2016.12.015"},{"issue":"1","key":"2873_CR10","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s10637-013-0045-6","volume":"32","author":"JE Rosenberg","year":"2014","unstructured":"Rosenberg JE, Bambury RM, Van Allen EM, Drabkin HA, Lara PN Jr, Harzstark AL, et al. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Investig New Drugs. 2014;32(1):178\u201387.","journal-title":"Investig New Drugs"},{"issue":"21","key":"2873_CR11","doi-asserted-by":"crossref","first-page":"8617","DOI":"10.1158\/0008-5472.CAN-10-0920","volume":"70","author":"EM Reyes-Reyes","year":"2010","unstructured":"Reyes-Reyes EM, Teng Y, Bates PJ. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. Cancer Res. 2010;70(21):8617\u201329.","journal-title":"Cancer Res"},{"key":"2873_CR12","doi-asserted-by":"crossref","first-page":"102060","DOI":"10.1016\/j.nano.2019.102060","volume":"21","author":"S Kabirian-Dehkordi","year":"2019","unstructured":"Kabirian-Dehkordi S, Chalabi-Dchar M, Mertani HC, Le Guellec D, Verrier B, Diaz JJ, et al. AS1411-conjugated gold nanoparticles affect cell proliferation through a mechanism that seems independent of nucleolin. Nanomedicine. 2019;21:102060.","journal-title":"Nanomedicine."},{"issue":"1","key":"2873_CR13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.copbio.2007.01.004","volume":"18","author":"BA Kaufmann","year":"2007","unstructured":"Kaufmann BA, Lindner JR. Molecular imaging with targeted contrast ultrasound. Curr Opin Biotechnol. 2007;18(1):11\u20136.","journal-title":"Curr Opin Biotechnol"},{"issue":"10","key":"2873_CR14","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1517\/17425247.5.10.1121","volume":"5","author":"CR Mayer","year":"2008","unstructured":"Mayer CR, Geis NA, Katus HA, Bekeredjian R. Ultrasound targeted microbubble destruction for drug and gene delivery. Expert Opin Drug Deliv. 2008;5(10):1121\u201338.","journal-title":"Expert Opin Drug Deliv"},{"key":"2873_CR15","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.biomaterials.2015.08.007","volume":"69","author":"NA Fonseca","year":"2015","unstructured":"Fonseca NA, Rodrigues AS, Rodrigues-Santos P, Alves V, Greg\u00f3rio AC, Val\u00e9rio-Fernandes \u00c2, et al. Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination. Biomaterials. 2015;69:76\u201388.","journal-title":"Biomaterials."},{"issue":"10","key":"2873_CR16","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3390\/cancers10100390","volume":"10","author":"F Nguyen Van Long","year":"2018","unstructured":"Nguyen Van Long F, Lardy-Cleaud A, Bray S, Chabaud S, Dubois T, Diot A, et al. Druggable Nucleolin Identifies Breast Tumours Associated with Poor Prognosis That Exhibit Different Biological Processes. Cancers (Basel). 2018;10(10):390.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2873_CR17","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.7150\/thno.16532","volume":"7","author":"Y Wang","year":"2017","unstructured":"Wang Y, Chen X, Tian B, Liu J, Yang L, Zeng L, et al. Nucleolin-targeted extracellular vesicles as a versatile platform for biologics delivery to breast Cancer. Theranostics. 2017;7(5):1360\u201372.","journal-title":"Theranostics."},{"key":"2873_CR18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.critrevonc.2018.03.008","volume":"125","author":"AC Greg\u00f3rio","year":"2018","unstructured":"Greg\u00f3rio AC, Lacerda M, Figueiredo P, Sim\u00f5es S, Dias S, Moreira JN. Meeting the needs of breast cancer: a nucleolin's perspective. Crit Rev Oncol Hematol. 2018;125:89\u2013101.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"2873_CR19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.addr.2010.03.011","volume":"63","author":"V Torchilin","year":"2011","unstructured":"Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011;63(3):131\u20135.","journal-title":"Adv Drug Deliv Rev"},{"issue":"10","key":"2873_CR20","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.7863\/jum.2012.31.10.1531","volume":"31","author":"S Wojcinski","year":"2012","unstructured":"Wojcinski S, Soliman AA, Schmidt J, Makowski L, Degenhardt F, Hillemanns P. Sonographic features of triple-negative and non-triple-negative breast cancer. J Ultrasound Med. 2012;31(10):1531\u201341.","journal-title":"J Ultrasound Med"},{"key":"2873_CR21","doi-asserted-by":"crossref","unstructured":"Dogan BE, Turnbull LW. Imaging of triple-negative breast cancer. Ann Oncol. 2012; 23 Suppl 6: vi23\u2013vi29.","DOI":"10.1093\/annonc\/mds191"},{"issue":"5","key":"2873_CR22","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00330-009-1656-3","volume":"20","author":"ES Ko","year":"2010","unstructured":"Ko ES, Lee BH, Kim HA, Noh WC, Kim MS, Lee SA. Triple-negative breast cancer: correlation between imaging and pathological findings. Eur Radiol. 2010;20(5):1111\u20137.","journal-title":"Eur Radiol"},{"issue":"3","key":"2873_CR23","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1148\/radiology.212.3.r99se18609","volume":"212","author":"R Weissleder","year":"1999","unstructured":"Weissleder R. Molecular imaging: exploring the next frontier. Radiology. 1999;212(3):609\u201314.","journal-title":"Radiology."},{"issue":"19","key":"2873_CR24","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2016.71.9997","volume":"35","author":"GJ Whitman","year":"2017","unstructured":"Whitman GJ, Hortobagyi GN. Ultrasound molecular imaging: a good start. J Clin Oncol. 2017;35(19):2101\u20132.","journal-title":"J Clin Oncol"},{"key":"2873_CR25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cbpa.2018.03.017","volume":"45","author":"A Zlitni","year":"2018","unstructured":"Zlitni A, Gambhir SS. Molecular imaging agents for ultrasound. Curr Opin Chem Biol. 2018;45:113\u201320.","journal-title":"Curr Opin Chem Biol"},{"issue":"3","key":"2873_CR26","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s11307-017-1058-x","volume":"19","author":"CF Caskey","year":"2017","unstructured":"Caskey CF. Ultrasound molecular imaging and drug delivery. Mol Imaging Biol. 2017;19(3):336\u201340.","journal-title":"Mol Imaging Biol"},{"issue":"6","key":"2873_CR27","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s11095-013-1100-x","volume":"31","author":"RH Perera","year":"2014","unstructured":"Perera RH, Solorio L, Wu H, Gangolli M, Silverman E, Hernandez C, et al. Nanobubble ultrasound contrast agents for enhanced delivery of thermal sensitizer to tumors undergoing radiofrequency ablation. Pharm Res. 2014;31(6):1407\u201317.","journal-title":"Pharm Res"},{"issue":"1","key":"2873_CR28","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s00259-010-1449-6","volume":"37","author":"JR Eisenbrey","year":"2010","unstructured":"Eisenbrey JR, Forsberg F. Contrast-enhanced ultrasound for molecular imaging of angiogenesis. Eur J Nucl Med Mol Imaging. 2010;37(1):138\u201346.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"2873_CR29","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.3390\/ijms13066679","volume":"13","author":"SA Moestue","year":"2012","unstructured":"Moestue SA, Gribbestad IS, Hansen R. Intravascular targets for molecular contrast-enhanced ultrasound imaging. Int J Mol Sci. 2012;13(6):6679\u201397.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"2873_CR30","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.7150\/thno.15169","volume":"6","author":"L Abou-Elkacem","year":"2016","unstructured":"Abou-Elkacem L, Wilson KE, Johnson SM, Chowdhury SM, Bachawal S, Hackel BJ, et al. Ultrasound molecular imaging of the breast Cancer Neovasculature using engineered Fibronectin scaffold ligands: a novel class of targeted contrast ultrasound agent. Theranostics. 2016;6(11):1740\u201352.","journal-title":"Theranostics."},{"issue":"2","key":"2873_CR31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/RLI.0b013e3181c5927c","volume":"45","author":"S Pochon","year":"2010","unstructured":"Pochon S, Tardy I, Bussat P, Bettinger T, Brochot J, von Wronski M, et al. BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis. Investig Radiol. 2010;45(2):89\u201395.","journal-title":"Investig Radiol"},{"issue":"19","key":"2873_CR32","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1200\/JCO.2016.70.8594","volume":"35","author":"JK Willmann","year":"2017","unstructured":"Willmann JK, Bonomo L, Testa AC, Rinaldi P, Rindi G, Valluru KS, et al. Ultrasound molecular imaging with BR55 in patients with breast and ovarian lesions: first-in-human results. J Clin Oncol. 2017;35(19):2133\u201340.","journal-title":"J Clin Oncol"},{"key":"2873_CR33","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.biomaterials.2016.11.026","volume":"118","author":"H Zhang","year":"2017","unstructured":"Zhang H, Ingham ES, Gagnon MK, Mahakian LM, Liu J, Foiret JL, et al. In vitro characterization and in vivo ultrasound molecular imaging of nucleolin-targeted microbubbles. Biomaterials. 2017;118:63\u201373.","journal-title":"Biomaterials."},{"issue":"30","key":"2873_CR34","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.1073\/pnas.1507087112","volume":"112","author":"D Palmieri","year":"2015","unstructured":"Palmieri D, Richmond T, Piovan C, Sheetz T, Zanesi N, Troise F, et al. Human anti-nucleolin recombinant immunoagent for cancer therapy. Proc Natl Acad Sci U S A. 2015;112(30):9418\u201323.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"2873_CR35","doi-asserted-by":"crossref","first-page":"7181","DOI":"10.1158\/0008-5472.CAN-16-0300","volume":"76","author":"ME Gilles","year":"2016","unstructured":"Gilles ME, Maione F, Cossutta M, Carpentier G, Caruana L, Di Maria S, et al. Nucleolin targeting impairs the progression of pancreatic Cancer and promotes the normalization of tumor vasculature. Cancer Res. 2016;76(24):7181\u201393.","journal-title":"Cancer Res"},{"issue":"3","key":"2873_CR36","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1021\/nn507494p","volume":"9","author":"YH Lao","year":"2015","unstructured":"Lao YH, Phua KK, Leong KW. Aptamer nanomedicine for cancer therapeutics: barriers and potential for translation. ACS Nano. 2015;9(3):2235\u201354.","journal-title":"ACS Nano"},{"key":"2873_CR37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.addr.2018.08.005","volume":"134","author":"G Zhu","year":"2018","unstructured":"Zhu G, Chen X. Aptamer-based targeted therapy. Adv Drug Deliv Rev. 2018;134:65\u201378.","journal-title":"Adv Drug Deliv Rev"},{"issue":"19","key":"2873_CR38","first-page":"37475","volume":"S0141-8130","author":"R Yazdian-Robati","year":"2019","unstructured":"Yazdian-Robati R, Bayat P, Oroojalian F, Zargari M, Ramezani M, Taghdisi SM, et al. Therapeutic applications of AS1411 aptamer, an update review. Int J Biol Macromol. 2019;S0141-8130(19):37475\u20136.","journal-title":"Int J Biol Macromol"},{"issue":"7","key":"2873_CR39","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1021\/ar8002442","volume":"42","author":"KW Ferrara","year":"2009","unstructured":"Ferrara KW, Borden MA, Zhang H. Lipid-shelled vehicles: engineering for ultrasound molecular imaging and drug delivery. Acc Chem Res. 2009;42(7):881\u201392.","journal-title":"Acc Chem Res"},{"issue":"2","key":"2873_CR40","doi-asserted-by":"crossref","first-page":"462","DOI":"10.7150\/thno.37593","volume":"10","author":"L Duan","year":"2020","unstructured":"Duan L, Yang L, Jin J, Yang F, Liu D, Hu K, et al. Micro\/nano-bubble-assisted ultrasound to enhance the EPR effect and potential theranostic applications. Theranostics. 2020;10(2):462\u201383.","journal-title":"Theranostics."},{"issue":"32","key":"2873_CR41","doi-asserted-by":"crossref","first-page":"325102","DOI":"10.1088\/0957-4484\/24\/32\/325102","volume":"24","author":"X Fan","year":"2013","unstructured":"Fan X, Wang L, Guo Y, Tong H, Li L, Ding J, et al. Experimental investigation of the penetration of ultrasound nanobubbles in a gastric cancer xenograft. Nanotechnology. 2013;24(32):325102.","journal-title":"Nanotechnology."},{"issue":"1","key":"2873_CR42","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12951-017-0307-0","volume":"15","author":"L Zhu","year":"2017","unstructured":"Zhu L, Guo Y, Wang L, Fan X, Xiong X, Fang K, et al. Construction of ultrasonic nanobubbles carrying CAIX polypeptides to target carcinoma cells derived from various organs. J Nanobiotechnology. 2017;15(1):63.","journal-title":"J Nanobiotechnology"},{"issue":"1\u20132","key":"2873_CR43","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0378-5173(97)00415-8","volume":"162","author":"PS Uster","year":"1998","unstructured":"Uster PS, Working PK, Vaage J. Pegylated liposomal doxorubicin (DOXIL\u00ae, CAELYX\u00ae) distribution in tumour models observed with confocal laser scanning microscopy. Int J Pharm. 1998;162(1\u20132):77\u201386.","journal-title":"Int J Pharm"},{"issue":"1","key":"2873_CR44","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ijpharm.2013.02.046","volume":"454","author":"T Lammers","year":"2013","unstructured":"Lammers T. Smart drug delivery systems: back to the future vs. clinical reality. Int J Pharm. 2013;454(1):527\u20139.","journal-title":"Int J Pharm"},{"issue":"5","key":"2873_CR45","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41563-019-0566-2","volume":"19","author":"S Sindhwani","year":"2020","unstructured":"Sindhwani S, Syed AM, Ngai J, Kingston BR, Maiorino L, Rothschild J, et al. The entry of nanoparticles into solid tumours. Nat Mater. 2020;19(5):566\u201375.","journal-title":"Nat Mater"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-020-02873-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-020-02873-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-020-02873-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T23:16:12Z","timestamp":1626218172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-020-02873-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["2873"],"URL":"https:\/\/doi.org\/10.1007\/s11095-020-02873-1","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"17 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"145"}}